Also known as: BI 456906
Survodutide is a synthetic, fatty-acid-modified peptide that activates both the glucagon and GLP-1 receptors and is designed as a long-acting peptide. It has peer-reviewed phase 2 and phase 3 human trial publications plus mouse pharmacology studies.
Survodutide is an acylated peptide (C18 fatty acid) that activates both the glucagon receptor and the GLP-1 receptor; in mice, GLP-1 receptor engagement was tracked by food intake, gastric emptying and glucose tolerance, and glucagon receptor engagement by liver NNMT expression, circulating amino acids and FGF-21 [5]. In mice, its body-weight effect was attributed to both reduced food intake and increased energy expenditure [5]. Work with a close structural analogue suggests the liver glucagon receptor drives part of the added effect over GLP-1-only agonism; this is proposed, not shown for survodutide itself [6].
| Study | Model | Reported result | Source |
|---|---|---|---|
| Phase 2 dose-finding trial [1] | Human Adults, randomized, double-blind, placebo-controlled | Phase 2, 387 adults, 46 weeks (20 escalation + 26 maintenance). Primary endpoint: percent change in body weight. Published. | Peer-reviewed Lancet Diabetes Endocrinol 2024 |
| Phase 2 liver-histology trial [2] | Human Adults with biopsy-assessed liver changes, randomized, placebo-controlled | Phase 2, 293 adults, 48 weeks, three dose levels. Primary endpoint: histologic change on liver biopsy without fibrosis worsening. Published. | Peer-reviewed N Engl J Med 2024 |
| SYNCHRONIZE-1 [3] | Human Adults, randomized, double-blind, placebo-controlled | Phase 3, 725 adults, 76 weeks, two dose levels. Primary endpoints: percent change in body weight and related responder measure. Published. | Peer-reviewed N Engl J Med 2026 |
| SYNCHRONIZE-2 [4] | Human Adults in a separate glycemic population, randomized, double-blind, placebo-controlled | Phase 3, 755 adults, 76 weeks. Primary endpoints: prespecified metabolic measures (see publication). Published. | Peer-reviewed N Engl J Med 2026 |
| Discovery and preclinical pharmacology [5] | Mouse Cell receptor assays; diet-induced obesity mouse model; GLP-1R knockout and reporter mice | Researchers compared body-weight effects with semaglutide in mice and related differences to energy expenditure and food intake; see publication. | Peer-reviewed Mol Metab 2022 |
| Liver glucagon-receptor knockout (analogue) [6] | Mouse High-fat-diet model; wild-type vs liver-specific GCGR-knockout mice; analogue BI-456908, 28 days | Researchers compared body-weight and liver-triglyceride effects in wild-type vs knockout mice; effects diminished in knockout mice. | Peer-reviewed Diabetes Obes Metab 2025 |
Human trials are listed for research context only; outcomes are reported in the linked publications. Animal and lab results do not establish effects in humans.
PureLab does not supply this compound. This page summarizes published research only.
